Two injections, two different jobs

Patients considering both options often ask the same question: 'They're both knee injections at a similar price — which one should I have?' The honest answer is that this framing misses something important. ChondroFiller and Arthrosamid are not two versions of the same treatment competing for the same knee problem; they are designed for structurally different problems and work through entirely different mechanisms.

ChondroFiller is a resorbable Type I collagen scaffold. Injected under ultrasound guidance as an outpatient procedure, it recruits the patient's own progenitor cells into its matrix to support cartilage repair at a focal defect site. It is gradually replaced by the body's own tissue over one to two years. Its role is regenerative.

Arthrosamid is a non-absorbable polyacrylamide hydrogel. A single 6 mL injection integrates with the synovial membrane and remains in the joint permanently, cushioning the joint and reducing friction across a diffuse, worn surface. It does not repair cartilage. Its role is sustained symptomatic relief.

Both are delivered as outpatient, ultrasound-guided intra-articular injections at broadly comparable UK private costs. That procedural similarity can lead patients to treat them as interchangeable — they are not. The sections below set out the mechanism, evidence, and patient-selection framework that determines which, if either, is appropriate.

How ChondroFiller works inside the knee

Injected as a liquid under ultrasound guidance, ChondroFiller's acid-extracted Type I collagen self-stabilises within three to five minutes at the defect site, forming a three-dimensional matrix — think of it as a temporary lattice that gives the patient's own cells a structure to grow into. The process driving repair is acellular matrix-induced chondrogenesis: progenitor cells migrate from the surrounding synovium and subchondral bone into the scaffold and begin producing cartilage-like tissue from within. A 2025 ex vivo osteochondral explant study measured a 2.4-fold increase in DNA content inside the ChondroFiller matrix by day 14, confirming that cell recruitment and retention occur at a clinically meaningful rate.

The device is CE-marked as a Class III medical device (Meidrix Biomedicals GmbH). Over approximately one to two years it is progressively resorbed and replaced by the patient's own repair tissue. ChondroFiller does not directly regrow cartilage; it supports the body's own repair processes by providing a structural environment for those processes to occur.

Its primary indication is focal Grade III–IV cartilage defects in patients whose joint is otherwise structurally reasonable. An evolving clinical pathway is assessing its use as an injectable scaffold for more advanced KL Grade III–IV knee OA — where the gel is draped across degenerated articular surfaces rather than confined to a single defect — but this remains a developing clinical practice and is not a licensed indication; specialist MRI and weight-bearing X-ray assessment are required to establish candidacy.

One practical consideration: a 2024 biomechanical in-vitro study found that the scaffold cannot adequately protect opposing cartilage surfaces under full cyclic loading before it has stabilised. A period of protected weight-bearing is therefore advisable after the injection while the matrix consolidates.

How Arthrosamid works inside the knee

Arthrosamid's therapeutic action begins at the synovial membrane rather than the cartilage surface. Once placed by ultrasound-guided intra-articular injection, the 97.5% water / 2.5% cross-linked polyacrylamide hydrogel adheres to and bulks up the synovial lining, acting as a durable mechanical buffer that reduces joint load and friction across the joint space. A systematic review pooling 463 patients reported statistically significant WOMAC improvements to at least two years; a 2026 review documented pain score reductions of 15.7 to 20.8 points across six months to three years of follow-up. Transient post-injection pain occurred in approximately 16% of patients, with no serious complications recorded.

The hydrogel is non-biodegradable: it does not resorb, is not replaced by host tissue, and does not require repeat injections on the schedule that resorbable treatments do. That permanence is both its primary clinical advantage — one injection, sustained effect — and the main consideration for patients to weigh, since the product remains in the joint indefinitely.

Arthrosamid does not recruit progenitor cells, provide a regenerative scaffold, or repair worn cartilage. Its target population is adults with moderate-to-severe diffuse knee OA seeking sustained symptom relief rather than structural repair. It is contraindicated in inflammatory arthritis, including rheumatoid arthritis, and is considered less appropriate where OA is so advanced that total knee replacement is the preferred clinical option. That indication boundary — diffuse, symptomatic OA in a joint that retains some structural integrity — separates it from ChondroFiller's focal-defect remit.

What the clinical evidence shows

ChondroFiller

The published clinical record for ChondroFiller in the knee is small but internally consistent. A 2016 prospective randomised multicentre study — 13 patients receiving ChondroFiller against 10 treated with microfracture — demonstrated statistically significant IKDC score improvements at 3, 6, and 12 months, with MRI at 4 and 52 weeks confirming good defect filling and progressive cartilage maturation (MOCART scores 70–87). A 2024 Bulgarian single-centre case series (n=17, mean age 31) replicated those outcome trajectories at the same time points; the absence of a significant difference between 6- and 12-month Lysholm and IKDC scores suggests the improvement stabilises rather than regresses within the first year. The most honest caveat is sample size: the 2016 RCT enrolled 13 patients in the ChondroFiller arm, and durability data beyond 12 months in knee patients remains sparse. That gap merits acknowledgement in any candidacy discussion.

Arthrosamid

Arthrosamid's evidence base is wider in patient numbers and longer in published follow-up. A systematic review pooling 463 patients reported statistically significant WOMAC improvements sustained to at least two years, and a 2026 review documented WOMAC pain reductions of 15.7 to 20.8 points across six months to three years of follow-up. In a published RCT, Arthrosamid showed numerical superiority over hyaluronic acid. Transient post-injection pain occurred in approximately 16% of cases, and no serious adverse events were recorded across the pooled data. A separate 2022 case series by Maulana, Cole, and Lee found a reduction in patellofemoral bone marrow lesions following a single injection — an additional signal, beyond symptom relief, that warrants attention in patients with patellofemoral involvement.

No published head-to-head trial exists between the two products; given that they are designed for different clinical problems, the disparity in evidence volumes reflects their separate development histories rather than any direct ranking of one over the other.

Which patients suit which treatment

The two central clinical filters are OA pattern and imaging findings — not age alone. A younger patient with widespread joint degeneration may be better placed for Arthrosamid; an older patient with a discrete, identifiable cartilage lesion in an otherwise structurally reasonable knee may be a stronger ChondroFiller candidate. What the MRI and weight-bearing X-ray show is what drives the conversation.

ChondroFiller tends to suit:

• Patients with a focal, identifiable Grade III or IV cartilage defect in a joint that retains reasonable overall structure
• Younger or more active individuals whose goal is to support the body's own repair processes rather than to manage symptoms alone
• Those who can observe a period of protected weight-bearing after the injection — a 2024 biomechanical study found the gel cannot fully protect opposing cartilage from contact stress under full cyclic loading until the scaffold has stabilised, making that recovery window a real practical consideration for working-age patients

Arthrosamid tends to suit:

• Adults with moderate-to-severe diffuse knee OA (typically KL Grade II–IV) where cartilage damage is broad rather than localised to a single identifiable lesion
• Patients whose primary goal is durable symptom relief — sustained comfort to delay or avoid joint replacement — rather than structural repair
• Those for whom a single permanent injection with no post-procedure loading restriction fits better with daily life or work commitments

Neither list is a checklist for self-selection. Some patients present features of both — a focal area of severe damage within a joint that also shows diffuse wear. In those cases, distinguishing which problem is driving the symptoms and which treatment addresses it requires consultant-led assessment with MRI and weight-bearing X-ray rather than pattern-matching to a shortlist.

Professor Paul YF Lee, who was the first clinician in the UK to perform both ChondroFiller and Arthrosamid injections commercially and has since treated more than 600 Arthrosamid patients, is in a position to advise on which pathway — or combination — fits a specific imaging and clinical picture. Lincolnshire Knee, as part of the MSK Doctors group, accepts patients without referral; an assessment can be arranged at lincolnshireknee.co.uk.

What the assessment and procedure involve

Both procedures are delivered in an outpatient clinic setting — no theatre admission, no incisions, no general anaesthetic. Each is placed under real-time ultrasound guidance as a single intra-articular injection, typically completed within one appointment.

Before the procedure

For ChondroFiller, a current MRI and weight-bearing X-ray are required before candidacy is confirmed; imaging establishes defect grade, joint alignment, and overall structural context. Arthrosamid assessment involves an equivalent imaging review to confirm OA severity and exclude contraindications — notably inflammatory or rheumatoid arthritis, for which the treatment is not appropriate.

After the injection

The two treatments diverge most clearly here. ChondroFiller carries a period of modified weight-bearing while the scaffold stabilises — the biomechanical rationale for that precaution is set out in the mechanism and patient-selection sections — and patients should factor that adjustment into their planning before committing. Arthrosamid post-injection discomfort is generally short-lived; most patients return to normal activity without a formal loading restriction.

Cost

UK private clinic guide costs for both treatments fall in the low-to-mid thousands of pounds — published figures from established providers sit broadly in the £2,770–£3,000 range — but the final figure depends on the full assessment package and should be confirmed directly at the point of consultation.

The practical decision comes down to one distinction: is the primary problem a focal defect in a structurally reasonable joint, or widespread symptom burden from diffuse OA? MRI and weight-bearing imaging make that call with precision; pattern-matching to a shortlist cannot. Lincolnshire Knee is part of the MSK Doctors group and accepts patients without referral — assessments can be arranged at lincolnshireknee.co.uk.

1. [1] Implantation of ChondroFiller Liquid® as a scaffold for chondral lesions of the knee joint. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
2. [2] Ex Vivo Osteochondral Biomimetic Platform for Cartilage Regeneration (ChondroFiller). (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
3. [3] Controlled, randomized multicenter study: ChondroFiller liquid vs microfracturing for focal cartilage defects of the knee. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
4. [4] Influence of cartilage defects and collagen gel on intact cartilage: biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z
5. [5] Inflammatory markers in the knee in OA assessed with ultrasound: Arthrosamid vs Synvisc-One RCT secondary analysis. (2024). https://doi.org/10.1016/j.joca.2024.03.100 https://doi.org/10.1016/j.joca.2024.03.100
6. [6] Intra-articular Arthrosamid® injection for knee osteoarthritis: A synovial fluid biomarker study. (2025). https://doi.org/10.1016/j.joca.2025.02.214 https://doi.org/10.1016/j.joca.2025.02.214
7. [7] A single injection of intra-articular Arthrosamid for knee OA — clinical efficacy and mechanism. (2025). https://doi.org/10.1016/j.joca.2025.02.767 https://doi.org/10.1016/j.joca.2025.02.767
8. [8] The impact of patient factors on the MCID of Arthrosamid polyacrylamide hydrogel injection for knee OA: a cohort study. (2025). https://doi.org/10.1016/j.joca.2025.02.648 https://doi.org/10.1016/j.joca.2025.02.648